Non-Invasive Method of Diagnosing Rejection for Liver Transplant Patients


About this study

The purpose of this study is to validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients who meet all of the following criteria are eligible for enrollment as study participants:

  1. Adult ( ≥ 18 years) liver transplant recipient.
  2. Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.
  3. Patients with increased risk of rejection. Patients must meet at least one of the following criteria:
    1. Autoimmune etiology of the original liver disease (autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis)
    2. Recipients of donation-after-cardiac death (DCD) donors
    3. Recipients of simultaneous liver-kidney transplantation
    4. Positive crossmatch liver transplant (T cell flow crossmatch or B cell flow crossmatch).
    5. Patients who underwent liver transplantation for PSC in the past, with recurrent disease (total of 4 patients)
    6. Patients who underwent liver transplantation for NASH (nonalcoholic steatohepatitis).
    7. Patients who have a BMI ≥ 35.

Exclusion Criteria

Patients who meet any of these criteria are not eligible for enrollment as study participants:

  1. Adult ( ≥ 18 years) renal transplant recipient.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Kristopher Croome, M.D.

Closed for enrollment

Contact information:

Joel Espinoza B.S.

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Adyr Moss, M.D.

Closed for enrollment

Contact information:

Samantha Parker D.T.R.

(480) 342-6677

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Closed for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer